Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022Motoko Yanagita, Naoki Kashihara, Takahiro Hatta et al.|Clinical and Experimental Nephrology|2023Cited by 13
Rituximab-induced long-term remission in childhood-onset, uncomplicated, frequently relapsing or steroid-dependent nephrotic syndrome: a randomized, placebo-controlled trial and a follow-up studyKazumoto Iijima, Yosuke Inaguma, Mayumi Sako et al.|Scientific Reports|2025Cited by 5
Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022Motoko Yanagita, Naoki Kashihara, Satoru Muto et al.|Clinical and Experimental Nephrology|2023Cited by 1
Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022Kenji Ishikura, Motoko Yanagita, Kenji Omae et al.|International Journal of Clinical Oncology|2023Cited by 0